Galderma has launched Alastin, its regenerative skincare line, across Japan and key Asia Pacific markets, expanding the company's footprint beyond its core injectables and energy-device portfolio. Alastin—featuring peptide-based and growth-factor technologies—targets post-procedure recovery and preventive aging, positioning as a complementary revenue stream to procedural services.
Market
Galderma Expands Alastin Regenerative Skincare Across Asia Pacific — Broadening the Non-Invasive Portfolio
The Swiss aesthetics giant launches its post-procedure and preventive skincare line in Japan and key APAC markets.
Galderma extends regenerative skincare into Japan and Asia Pacific, broadening non-invasive revenue.
For medspa owners, Alastin's APAC rollout underscores Galderma's strategy to build skincare-adjacent revenue alongside Dysport and Radiesse. The product line typically carries 60–70% gross margins and drives patient loyalty through at-home regimens. Galderma's distribution model—direct-to-practice and through authorized wholesalers—means practices in markets with Alastin availability should evaluate shelf space and patient education ROI. The brand has gained traction in North America; international expansion validates the model and may signal accelerated domestic marketing.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.